Mar 18, 2026 07:57AM H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)

Mar 17, 2026 05:58PM Stifel Reiterates Buy Rating on Alto Neuroscience (ANRO) as co on track for ph2b TRD study for ALTO-207

Mar 16, 2026 10:56AM Alto Neuroscience (ANRO) PT Raised to $35 at Jefferies

Jan 14, 2026 07:27AM Alto Neuroscience receives patent for ALTO-207 depression treatment method

Jan 5, 2026 07:29AM Chardan Capital Markets Assumes Alto Neuroscience (ANRO) at Buy

Nov 28, 2025 06:03AM Alto Neuroscience (ANRO) files for 8.45M share offering by selling stockholders

Nov 17, 2025 05:35AM BTIG Starts Alto Neuroscience (ANRO) at Buy

Nov 13, 2025 04:21AM Alto Neuroscience (ANRO) PT Raised to $22 at Baird

Nov 12, 2025 04:50PM Alto Neuroscience, Inc. (ANRO) Tops Q3 EPS by 12c

Oct 24, 2025 06:49AM Alto Neuroscience (ANRO) PT Raised to $50 at H.C. Wainwright

Oct 20, 2025 10:59AM Alto Neuroscience (ANRO) PT Raised to $16 at Baird

Oct 20, 2025 07:01AM Alto Neuroscience plans Phase 3 depression drug study by early 2027

Sep 29, 2025 05:59AM Chardan Capital Markets Starts Alto Neuroscience (ANRO) at Buy, PT $15

Sep 15, 2025 07:37AM H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)

Sep 9, 2025 07:09AM Alto Neuroscience validates EEG biomarker for schizophrenia diagnosis

Aug 13, 2025 06:04PM Alto Neuroscience, Inc. (ANRO) Misses Q2 EPS by 5c

Jun 30, 2025 08:03AM Alto Neuroscience (ANRO) Highlights Peer-Reviewed Publication of PAX-D Study

Jun 27, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)

Jun 26, 2025 03:09PM William Blair Reiterates Outperform Rating on Alto Neuroscience (ANRO)

Jun 26, 2025 10:56AM Stifel Positive on Alto Neuroscience (ANRO): 'ALTO-203 Shows Interesting Signs of Activity But Not Thesis Impacting'

Jun 26, 2025 07:33AM Alto Neuroscience (ANRO) Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 4, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)

Jun 3, 2025 06:14AM Alto Neuroscience (ANRO) Acquires Novel Dopamine Agonist Combination Product Candidate

May 29, 2025 08:04AM Alto Neuroscience (ANRO) Presents Data Reinforcing Safety and Tolerability Profile for ALTO-300

May 15, 2025 05:33PM Alto Neuroscience, Inc. (ANRO) Tops Q1 EPS by 1c

Feb 19, 2025 08:04AM Alto Neuroscience (ANRO) Announces U.S. Patent Granted Covering ALTO-300

Feb 12, 2025 10:09AM Stifel Positive on Alto Neuroscience (ANRO), PT $10, 'risk/reward here for the stock is favorable'

Feb 12, 2025 08:04AM Alto Neuroscience (ANRO) Announces Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Dec 16, 2024 07:04AM Jones Trading Starts Alto Neuroscience (ANRO) at Buy

Nov 13, 2024 04:46PM Alto Neuroscience, Inc. (ANRO) Misses Q3 EPS by 6c

Oct 23, 2024 06:44AM Rodman & Renshaw Downgrades Alto Neuroscience (ANRO) to Neutral

Oct 23, 2024 06:24AM Alto Neuroscience (ANRO) PT Lowered to $10 at Baird

Oct 22, 2024 04:44PM After-hours movers: McDonald's, Starbucks, Seagate, Alto Neuroscience and more

Oct 22, 2024 04:30PM Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100

Sep 10, 2024 08:25AM TD Cowen Reiterates Buy Rating on Alto Neuroscience (ANRO)

Sep 10, 2024 06:30AM Baird Reiterates Outperform Rating on Alto Neuroscience (ANRO)

Sep 9, 2024 03:36PM Stifel Recaps Alto Neuroscience (ANRO) Investor Day, 'risk/reward is favorable', Shares Gain ~7.3%

Sep 4, 2024 08:06AM Alto Neuroscience (ANRO) Reports Publication Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

Sep 3, 2024 06:21AM Wedbush Starts Alto Neuroscience (ANRO) at Outperform

Jul 25, 2024 08:34AM Alto Neuroscience (ANRO) Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

Jun 20, 2024 12:50PM Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation'